{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Bevetex Survey
Please help us understand some practical aspects of cancer pain management & its treatment in your practice. We would appreciate if you can take few moments to give your valuable comments in questionnaire below.
  1. Among all patients receiving conventional paclitaxel, how frequently do you see Grade3/4 hypersensitivity reactions? *

  2. As per your clinical experience, the occurrence of hypersensitivity reactions with nano-paclitaxel is*

  3. In your clinical practice, what % of your nano-paclitaxel prescriptions are in the following indications? *
    4. Ca Pancreas
    %
    Ca Breast
    %
    Ca Lung
    %
    Ca ovary
    %
    Head & Neck cancer
    %
    GI Cancers
    %
    %
  4. Among all your Nano-paclitaxel Rx, what % of Rx are in *
    5. Weekly Rx
    %
    3-weekly Rx
    %
  5. While prescribing weekly schedule for nano-paclitaxel, you prefer to chose *

  6. As you would be aware, Sun Pharma has developed a patented nano-paclitaxel formulation (PICN), Have you experienced BEVETEX in your patients? (Please tick) *

  7. Based on your clinical experience with BEVETEX, how will you rate the outcome till date is *

  8. As you would be aware, we have recently shown similarity between BEVETEX and nab-paclitaxel innovator from a USFDA guided BA/BE study. Phase 2 / 3 data comparing BEVETEX (PICN) VS nab-paclitaxel innovator in MBC has shown non-inferiority in efficacy and safety parameters *

    9. Based upon the available data on Bevetex, will you consider using BEVETEX interchangeably in all nab-paclitaxel innovator’s approved indications?

  9. Based on available data comparing BEVETEX with nab-paclitaxel innovator BA / BE study demonstrating equivalence, will you consider using Bevetex with gemcitabine in 1st line metastatic pancreatic cancer *

  10. BEVETEX (PICN) uses body’s natural albumin to transport nano particle paclitaxel to tumor tissues via the GP 60 receptors. GP60 receptors have got higher affinity towards natural albumin compared to processed albumin. Will you appreciate the fact that BEVETEX can be as good as nab-paclitaxel innovator in terms of mode of action? *

  11. Albumin is a functional component of nab-paclitaxel innovator. The biological activity is critical in assuring equivalence in safety and therapeutic effect. The FDA and other health authorities have acknowledged the significance of albumin in nab-paclitaxel innovator. *

    12. How assured you are about the source, quality and processing of albumin used by generic brands in India (Please tick)

  12. Apart from Bevetex, which of the other polymer bound nano-paclitaxel brands (available in India) has conducted head to head clinical study vs innovator nab-paclitaxel? *
  13. Which of the below mentioned albumin bound nano-paclitaxel brands (available in India) has conducted head to head clinical study vs innovator nab-paclitaxel? *
  14. While considering a new therapy in Neo-adjuvant chemotherapy (NACT) of Breast Cancer, which response is most critical for treatment decision?*

  15. Based upon the pathological complete response & disease-free survival advantage seen in GEPAR-SEPTO trial (nano-paclitaxel in NACT breast cancer), will you consider nano-paclitaxel in this setting? *

  16. Recently Nano-paclitaxel + Atezolizumab has shown remarkable response in TNBC. But as you would agree, affordability for this combination may be an issue for majority of Indian patients. *

    17. In patients, who can’t afford Atezolizumab + Nano-paclitaxel, will you prefer giving single agent nab over conventional paclitaxel?

  17. Of all the pancreatic cancers you see every year, what % of patients are *
    18. Local/locally advanced (eligible for surgery)
    %
    Metastatic disease
    %
  18. Of all the metastatic pancreatic cancers you see every year, what % of patients receive *
    19. Nano-paclitaxel+Gemcitabine
    %
    FOLFIRINOX
    %
    Best Supportive Care
    %
    %
  19. As you would aware, the current nano-paclitaxel’s used in India have different approved dose ranging between 220-300mg/m2. According to you how important it is for you to use a same dose like the nab-paclitaxel innovator i.e. 260mg/2 ? *

  20. As per your clinical experience, when you use 300mg/m2 of nano-paclitaxel instead of 260mg/m2 , the risk of neurotoxicity and hypersensitive reactions *

  21. As per your clinical experience, when you use 220mg/m2 of nano-paclitaxel instead of 260mg/m2, the efficacy outcomes are *